AbbVie, Biogen to file for FDA approval of MS drug (daclizumab), next year

Phase-III results of the AbbVie-Biogen Idec experimental multiple sclerosis shot Zinbryta (daclizumab) indicate the drug bests Biogen’s injectable Avonex (interferon beta-1a) on some measures among relapse-remitting MS patients.

The companies released the full results at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis last week.

The clinical trial of more than 1,800 patients showed Zinbryta patients had “significantly improved key measures of multiple sclerosis disease activity,” including a 45% reduction in relapses compared to Avonex patients and fewer new brain lesions. Researchers found that 73% of Zinbryta patients were relapse-free after 96 weeks of therapy, compared to Avonex patients, of whom 59% were relapse-free within the same timeframe.

~~~~~~~~~~~~~~~~~~~~

 Keep CURRENT and up to date, with MS News and Information

Sign-up for emails 

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews